These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22014409)

  • 1. Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases.
    Hussein O; Tiedemann K; Murshed M; Komarova SV
    Cancer Lett; 2012 Jan; 314(2):176-84. PubMed ID: 22014409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo.
    Cicek M; Iwaniec UT; Goblirsch MJ; Vrabel A; Ruan M; Clohisy DR; Turner RR; Oursler MJ
    Cancer Res; 2007 Nov; 67(21):10106-11. PubMed ID: 17974950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
    Abdelaziz DM; Stone LS; Komarova SV
    Breast Cancer Res Treat; 2014 Jan; 143(2):227-37. PubMed ID: 24327332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines.
    Ono K; Akatsu T; Murakami T; Kitamura R; Yamamoto M; Shinomiya N; Rokutanda M; Sasaki T; Amizuka N; Ozawa H; Nagata N; Kugai N
    J Bone Miner Res; 2002 May; 17(5):774-81. PubMed ID: 12009007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
    Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a V-ATPase inhibitor, FR202126, in syngeneic mouse model of experimental bone metastasis.
    Niikura K
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):555-62. PubMed ID: 17187252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future treatment of bone metastases.
    Lipton A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6305s-6308s. PubMed ID: 17062719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histochemical evidence of osteoclastic degradation of extracellular matrix in osteolytic metastasis originating from human lung small carcinoma (SBC-5) cells.
    Li M; Amizuka N; Takeuchi K; Freitas PH; Kawano Y; Hoshino M; Oda K; Nozawa-Inoue K; Maeda T
    Microsc Res Tech; 2006 Feb; 69(2):73-83. PubMed ID: 16456838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single pretreatment by zoledronic acid converts metastases from osteolytic to osteoblastic in the rat.
    Nyangoga H; Blouin S; Libouban H; Baslé MF; Chappard D
    Microsc Res Tech; 2010 Aug; 73(8):733-40. PubMed ID: 19953666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
    Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
    J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells.
    Takita M; Inada M; Maruyama T; Miyaura C
    FEBS Lett; 2007 Feb; 581(3):565-71. PubMed ID: 17254571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
    Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
    Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Abbey CK; Kim L; Damonte P; Borowsky AD; Qi J; Tepper CG; MacLeod CL; Cardiff RD; Gregg JP
    Clin Cancer Res; 2006 Apr; 12(8):2613-21. PubMed ID: 16638874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
    Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
    Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.
    Whang PG; Schwarz EM; Gamradt SC; Dougall WC; Lieberman JR
    J Orthop Res; 2005 Nov; 23(6):1475-83. PubMed ID: 16005175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.